HBK Investments’s Orchestra BioMed OBIO Stock Holding History

HBK Investments’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-69,237	Closed	-$690K	–	491
2022 Q2	$690K	Buy	69,237 +7,704	+13%	+$76.6K	﹤0.01%	426
2022 Q1	$610K	Hold	61,533	–	–	﹤0.01%	506
2021 Q4	$620K	Buy	+61,533	New	+$606K	﹤0.01%	517
2021 Q1	–	Sell	-47,800	Closed	-$612K	–	1036
2020 Q4	$612K	Hold	47,800	–	–	﹤0.01%	565
2020 Q3	$526K	Buy	+47,800	New	+$537K	﹤0.01%	517

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

HBK Investments's OBIO Position: Q3 2022 in Review

HBK Investments sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 69,237 shares — an estimated $690K sold.

HBK Investments first reported a position in OBIO in Q3 2020 and held it in 5 quarters. The position peaked at $690K in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

HBK Investments reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
HBK Investments sold 69,237 Orchestra BioMed shares in Q3 2022, an estimated $690K.
HBK Investments first reported a position in Orchestra BioMed in Q3 2020 and held it in 5 quarters.
HBK Investments's Orchestra BioMed position peaked at $690K in Q2 2022.
23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on HBK Investments's 13F filing for Q3 2022, filed 14 Nov 2022.